UK parliament backs hybrid embryo research

The UK Parliament has voted to allow the creation of embryos containing both human and animal genetic material for research purposes. As apart of a two-date debate on amendments to the Human Fertilisation and Embryology Bill, members of parliament voted 342 to 163 against an amendment to outlaw so-called hybrid or admixed embryos.

Prime Minister Gordon Brown also gave his backing to the use of these embryos in research. Writing in a column in the UK daily newspaper, the Guardian, Mr Brown said that these embryos would bring to an end "the critical limiting factor in stem cell research: the lack of human eggs from which to create embryos and collect stem cells". They would also bring new cures and treatments to millions of people.

"The doctors and scientists I speak to are committed to what they see as an inherently moral endeavour that can save and improve the lives of thousands and, over time, millions of people," writes the UK Prime Minister.

The creation of several types of admixed embryos are permitted under the Bill:

  • human-animal hybrids that are created using a human egg and the sperm of an animal, or an animal egg and a human sperm;
  • cytoplasmic hybrids or cybrids that are created by techniques used in cloning, using human cells and animal eggs. Cybrids would be mostly human except for the presence of animal mitochondria;
  • human transgenic embryos where animal DNA is introduced into one or more cells of the embryo;
  • human-animal chimeras where human embryos are altered by the addition of one or more cells from an animal.

The Bill states that these embryos will be allowed only where they are used for clear scientific purposes and it will be illegal to keep them for longer than 14 days. It will also be illegal to implant them into women or into any animals.

Speaking during the parliamentary debate, Edward Leigh, a Conservative MP and an opponent of the Bill, said that there was no large-scale body of evidence to suggest that research using hybrid embryos can cure any diseases. He referred to a letter written by a group of scientists which warned that such research could damage public confidence and support for stem cell research.

"The public have been misled - cruelly, in many cases - into thinking that such research could lead to early and useful cures by exaggeration, misinformation and hyperbole," he argued.

However, Ian Gibson, Labour MP for Norwich North, who is also a scientist, rejected such claims. "The reason scientists carry out research is that they have a hunch, an idea, perhaps on the basis of earlier work, which makes them say 'I wonder what would happen if...'. That is how science advances," he said.

"Scientists are fallible- they are not always on the right lines - but gosh, if the world did not have science we would not have the medical cures that we have, or, indeed, any understanding of climate change, about which many Members spout without knowing much about the science," added Dr Gibson.

For more information about the Bill, please visit:
http://www.parliament.uk/

Copyright ©European Communities, 2008
Neither the Office for Official Publications of the European Communities, nor any person acting on its behalf, is responsible for the use, which might be made of the attached information. The attached information is drawn from the Community R&D Information Service (CORDIS). The CORDIS services are carried on the CORDIS Host in Luxembourg - http://cordis.europa.eu. Access to CORDIS is currently available free-of-charge.

Most Popular Now

FDA grants Breakthrough Therapy Designation to Pfi…

Pfizer Inc. (NYSE:PFE) today announced that its investigational Group B Streptococcus (GBS) vaccine candidate, GBS6 or PF-06760805, received Breakthrough Therapy Designat...

Novartis invests in early technical development ca…

Novartis today announced it is investing in next-generation biotherapeutics with the creation of a fully integrated, dedicated USD 300m scientific environment that will b...

Pfizer and BioNTech receive positive CHMP opinion …

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced a 30-µg booster dose of their Omicron BA.4/BA.5 bivalent-adapted COVID-19 vaccine (COMIRNATY® Original/Om...

Malaria booster vaccine shows durable high efficac…

Researchers from the University of Oxford and their partners have today reported new findings from their Phase 2b trial following the administration of a booster dose of ...

Strict COVID lockdowns in France improved cardiova…

A new paper in European Heart Journal - Digital Health, published by Oxford University Press, indicates that social-distancing measures like total lockdown have a measura...

U.S. clinical trial evaluating antiviral for monke…

A Phase 3 clinical trial evaluating the antiviral tecovirimat, also known as TPOXX, is now enrolling adults and children with monkeypox infection in the United States. St...

Stem cell-gene therapy shows promise in ALS safety…

Cedars-Sinai investigators have developed an investigational therapy using support cells and a protective protein that can be delivered past the blood-brain barrier. This...

Drug turns cancer gene into "eat me" fla…

Tumor cells are notoriously good at evading the human immune system; they put up physical walls, wear disguises and handcuff the immune system with molecular tricks. Now...

Mucosal antibodies in the airways protect against …

High levels of mucosal antibodies in the airways reduce the risk of being infected by omicron, but many do not receive detectable antibodies in the airways despite three ...

WHO grants prequalification to GSK's Mosquirix - t…

GSK plc (LSE/NYSE: GSK) announced that the World Health Organization (WHO) has awarded prequalification to Mosquirix (also known as RTS,S/AS01), GSK's groundbreaking mala...

Bird's enzyme points toward novel therapies

Thank the rare crested ibis for a clue that could someday help our bodies make better drugs. The species of bird is the only one known to naturally produce an enzyme ...

WHO strongly advises against antibody treatments f…

The antibody drugs sotrovimab and casirivimab-imdevimab are not recommended for patients with COVID-19, says a WHO Guideline Development Group of international experts in...